2016 Biomax Symposium: Bringing big and complex data into clinical practice

24 June 2016, Martinsried, Germany.
Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsried (near Munich), Germany. This year's Biomax Symposium focuses on how clinical practice and patient treatment can benefit from big and complex data. It will cover the challenges and requirements that need to be addressed in a clinical setting: from gathering big data, guaranteeing data security in daily practice and fostering feedback between complex clinical data and research, to learning from the data to make better treatment decisions. In a nutshell, the symposium will cover using big and complex data to treat the individual with the knowledge of all.

Biomax has hosted this biennial event since 2012 to facilitate the discussion between clinical management and practitioners, pharma, "Big Data" researchers, health insurance payers, public health and government representatives, funding providers, as well as patient representatives. Through the symposium Biomax hopes to share their own and other experiences in implementing such programs. Past symposia have been a popular forum for these important players to learn from each other and discuss the way forward.

Invited speakers and panel discussion participants are leaders from clinical research, healthcare organizations, international research projects and government. The opening session includes presentations by:

  • Prof. Dr. Emiel Wouters, Department of Respiratory Medicine, University Medical Centre, Maastricht
  • Henning Schneider, CIO at the University Medical Center Hamburg-Eppendorf
  • Prof. Dr. Hans-Werner Mewes, School of Life Sciences, Technische Universität München

The symposium is free of charge.

For further information and to register, please visit:
http://www.biomax.com/symposiums/biomax-symposium-2016/

About Biomax
Biomax Informatics AG is a leader in the development of computational solutions for the life sciences. Biomax provides the BioXM™ Knowledge Management Environment and other computational solutions, including the Viscovery® data-mining technology, for better decision making and knowledge management in biomarker identification, patient stratification and targeted medicine. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes medical clinics, research organizations and companies that are successful in drug discovery, diagnostics, fine chemicals, food and plant production and healthcare.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]